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Background: Conjugated linoleic acids (CLA) in general, and in particular the trans-10,cis-12 (t10,c12-CLA) isomer
are potent modulators of milk fat synthesis in dairy cows. Studies in rodents, such as mice, have revealed that t10,
c12-CLA is responsible for hepatic lipodystrophy and decreased adipose tissue with subsequent changes in the fatty
acid distribution. The present study aimed to investigate the fatty acid distribution of lipids in several body tissues
compared to their distribution in milk fat in early lactating cows in response to CLA treatment. Effects in mammary
gland are further analyzed at gene expression level.
Methods: Twenty-five Holstein heifers were fed a diet supplemented with (CLA groups) or without (CON groups) a
rumen-protected CLA supplement that provided 6 g/d of c9,t11- and t10,c12-CLA. Five groups of randomly assigned
cows were analyzed according to experimental design based on feeding and time of slaughter. Cows in the first group
received no CLA supplement and were slaughtered one day postpartum (CON0). Milk samples were taken from the
remaining cows in CON and CLA groups until slaughter at 42 (period 1) and 105 (period 2) days in milk (DIM).
Immediately after slaughter, tissue samples from liver, retroperitoneal fat, mammary gland and M. longissimus (13th rib)
were obtained and analyzed for fatty acid distribution. Relevant genes involved in lipid metabolism of the mammary
gland were analyzed using a custom-made microarray platform.
Results: Both supplemented CLA isomers increased significantly in milk fat. Furthermore, preformed fatty acids
increased at the expense of de novo-synthesized fatty acids. Total and single trans-octadecenoic acids (e.g., t10-18:1 and
t11-18:1) also significantly increased. Fatty acid distribution of the mammary gland showed similar changes to those in
milk fat, due mainly to residual milk but without affecting gene expression. Liver fatty acids were not altered except for
trans-octadecenoic acids, which were increased. Adipose tissue and M. longissimus were only marginally affected by
CLA supplementation.
Conclusions: Daily supplementation with CLA led to typical alterations usually observed in milk fat depression
(reduction of de novo-synthesized fatty acids) but only marginally affected tissue lipids. Gene expression of the
mammary gland was not influenced by CLA supplementation.
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Conjugated linoleic acids (CLA) as products of partial
hydrogenation of polyunsaturated fatty acids (PUFA) in
ruminants [1], are attributed to have potent physiological
effects. Among the numerous different positional and geo-
metrical CLA isomers, cis-9,trans-11-18:2 (c9,t11-CLA) has
quantitatively the highest proportion of dairy products
whereas t10,c12-CLA is, besides c9,t11-CLA, mainly found
in synthetically assembled CLA products. Each isomer has
distinct chemical and biological properties, and may coun-
teract one another when provided as amixture. Distribution
of isomers and total amount of CLA in ruminant products
varies and depends on factors such as farmmanagement [2]
and feeding regimens [3]. Diets rich in PUFA such as for
instance linoleic or linolenic acid and marine oils have been
described to increase the amount of CLA in milk and tissue
lipids and to bring about a reduction of fat content in milk
of dairy cows [4,5]. This effect is termed low-fat milk
syndrome or milk fat depression (MFD). In their review
Bauman and Griinari [6] describe dietary induced MFD as
being associated with a shift in the process of biohy-
drogenation leading to the formation of intermediates such
as t10,c12-CLA and t10-18:1. Experiments with pure
abomasally infused isomers in lactating cows identified t10,
c12-CLA as the active isomer that decreases the concentra-
tion of milk fat [7] in a dose-dependent manner [8]. As a
frequent byproduct of MFD, t10-18:1 is also attributed to
reduce synthesis of milk fat in dairy cows [9,10], however
Lock et al. [11] observed that pure abomasally infused
t10-18:1 has no effect onmilk fat synthesis.
The ability of t10,c12-CLA to induce MFD is a matter
of interest, given that during early lactation nutritional
requirements of dairy cows increase dramatically owing
to the initiation of milk production [12]. The underlying
mechanism by which t10,c12-CLA lowers the milk fat
yield is due to reduced expression of lipogenic enzymes
and transcription factors involved in lipid synthesis
[13,14]. Hence, supplementation with rumen-protected
CLA is an attempt to influence the energy output during
the transition period and early lactation via milk fat. An
improvement in the net energy balance and a reduction
of body fat mobilization [15] diminish the incidence of
metabolic disorders such as ketosis and milk fever and,
in turn, the associated economic losses. In addition to its
milk fat-lowering effect, t10,c12-CLA is also described as
being capable of altering body composition by reducing
adipose tissue and increasing the hepatic lipid content in
different species [16-18]. These changes lead to alterations
in the fatty acid distribution of liver and adipose tissue
[19]. However, studies concerning these aspects have
rarely been conducted in ruminants.
The objective of the present study was to analyze
different tissue lipids from CLA-supplemented Holstein
heifers in early lactation. Herein, we provide new dataon CLA content and fatty acid distribution in liver,
mammary gland, muscle and adipose tissue. With this
new dataset a comparison between the effects of dietary
CLA in rodents and ruminants is provided. The results
of the fatty acid distribution in the mammary gland are
supported by gene expression analysis. Thereby, the ana-
lysis of milk lipids provides reliable estimates on the extent
ofMFD and the enrichment of CLA after supplementation.
Materials and methods
Animals, diets and experimental design
Details of experimental design and feeding regimen have
previously been published by von Soosten et al. [20]. In
brief, twenty-five primiparous lactating German Holstein
heifers were randomly assigned to 5 groups. All animals
received a prepartum diet consisting of a partial mixed
ration (PMR; 60% corn silage, 40% grass silage) ad
libitum and additionally 2 kg of concentrate/d. An initial
group of 5 cows (CON0) was slaughtered one day after
parturition. Starting at 1 day postpartum, the remaining
20 heifers were fed a PMR (38% corn silage, 25% grass
silage, 37% concentrate on dry matter basis) ad libitum,
and additionally, 3.5 kg of concentrate/d which contained
either 100 g of the CLA supplement (Lutrell® pure, BASF
SE, Ludwigshafen, Germany) or 100 g of a control fat
preparation (Silafat®, BASF SE). The CLA-supplemented
diet provided a mixture of 6.0 g/d of t10,c12-CLA and
5.7 g/d of c9,t11-CLA isomer. At 42 days in milk (DIM;
period 1), 5 cows from the control group (CON42) and 5
from the supplemented group (CLA42) were slaughtered.
At 105 DIM (period 2), a further 5 cows from the control
group (CON105) and 5 from the supplemented group
(CLA105) were slaughtered. All animals had free access to
water during the entire experimental trial. This animal
trial was approved by the Lower Saxony State Office for
Consumer Protection and Food Safety (LAVES, File No.
33.11.42502-04-071/07), Oldenburg, Germany.
Sample collection
Milk samples were collected twice a week and stored
at −20°C until freeze-dried. In addition, tissue samples
from liver, mammary gland, M. longissimus (13th rib),
and retroperitoneal adipose tissue were taken immedi-
ately after slaughter and stored at −20°C. Further, tissue
samples for gene expression analysis of the mammary
gland were also obtained and stored at −80°C.
Analysis of lipids
Lipids from the collected milk samples were extracted in
a Soxhlet apparatus using petroleum ether. The trans-
esterification of milk lipids into fatty acid methyl esters
(FAME) occurred as described by Kraft et al. [21].
Tissue samples were cut into small pieces and freeze-
dried. Lipids were extracted from the freeze-dried tissue
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to the method of Folch et al. [22]. Conversion from liver
and muscle tissue lipids into FAME was performed via
acid-catalyzed transesterification using boron trifluoride
(BF3) for 3 min upon prior ester cleavage with 0.5 M
methanolic sodium hydroxyde for 10 min [23]. Since
transesterification with BF3 is known to produce undesir-
able isomerization products of CLA [24], we reduced
transesterification time from 5 to 3 min to minimize this
problem. FAME were purified employing thin-layer chro-
matography (mobile phase: n-hexane/diethyl ether/glacial
acetic acid; 85:15:0.2 by volume). Lipids from mammary
gland and retroperitoneal adipose tissue were converted
into FAME by means of base-catalyzed transesterification
using 0.5 M sodium methoxide in anhydrous methanol.
Separation of the resulting FAME was undertaken via
gas chromatography (GC-17A v.3, Shimadzu, Japan) and
flame ionization detector (FID) in two steps. In the first
step, FAME with a chain length of 4 to 26 carbon atoms
were separated in a medium polar column (DB-225MS,
60 m × 0.25 mm i.d., 0.25 μm film thickness, Agilent
Technologies, USA) following a temperature program
[25]. In the second step, separation of cis and trans isomers
of octadecenoic FAMEwas performed using a high-polarity
column (Select™ FAME, 200 m × 0.25 mm i.d., 0.25 μm film
thickness, Varian, Netherlands) under isothermal condi-
tions at 176°C. Both separation steps possessed 260°C
and 270°C temperature settings for injector and FID,
respectively. Hydrogen was used as the carrier gas.
According to the retention time of several standard
mixtures, FAME were evaluated from all samples using an
analytical GC software (GCsolution Version 2.31, Shimadzu,
Japan).
To arrive at the final fatty acid distribution, a standard
mixture consisting of cis and trans isomers of octadecenoic
FAME was run on both columns. The total area of the trans
isomers of octadecenoic FAME fatty acids on the medium
polar column was repartitioned according to their individ-
ual peak areas on the high-polarity column using 18:0 from
both columns as reference peak areas.
Preparation of the microarray
Based on literature research and metabolic pathways, we
selected 96 candidate genes (see Additional file 1) related
to lipid and fatty acid metabolism (e.g., triacylglycerol
synthesis, beta-oxidation, and desaturation of fatty acids)
for the study. Gene expression analysis was performed
employing a custom-made array platform integrated into
a micro reaction tube (ArrayTube; Alere Technologies,
Jena, Germany). For this purpose, total RNA from tissue
samples (mammary gland) was extracted using the
RNeasy® Plus Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturers’ instructions. Concentra-
tion and purity of the obtained RNA were assessed withthe Nanodrop ND-1000 spectrophotometer (peQLab
Biotechnology, Erlangen, Germany). To perform micro-
array-experiments, 1.5 μg RNA was transcribed to comple-
mentary DNA (cDNA) by simultaneously labeling with
biotin-16-dUTP (RocheDiagnostics,Mannheim, Germany)
using an expand reverse transcriptase (Roche Diagnostics),
hexanucleotide random primer (Roche Diagnostics) and
dNTPs (Fermentas, St. Leon-Rot, Germany). Hybridization
was then undertaken via the kit obtained from Alere
Technologies. In brief, purified and concentrated cDNA
was hybridized to chip-bound oligonucleotides followed by
conjugation with horseradish peroxidase-linked strep-
tavidin. Subsequently, tetramethylbenzidine was added as
substrate for the horseradish peroxidase to form precipi-
tates. The precipitates were then recorded with a CCD-
based transmission device (ATR03, Alere Technologies),
and transferred to gray value data by means of a specialized
array analysis software (IconoClust version 3.6, Alere
Technologies).Analysis of expression data
Expression data was captured using the above described
custom array platform for mammary gland. In total, we
analyzed 62 chips with 111 probes each.
We applied an error correction pipeline [26] to filter
physical artefacts and defective chips were directly ex-
cluded. The most commonly used genes (ACTB,
GAPDH) did not show a stable expression pattern
across all chips. However, house-keeping genes or con-
trol sets, may suffer from unstable variance as previ-
ously described [27]. Thus, we relied on the frequently
used locally-weighted regression scatterplot smoothing
(LOWESS [28]) to normalize the set of arrays. Here, the
siggenes package was used [29] as part of the R-project.
We depended on case–control fold-changes with an as-
sociated moderated T-statistic (Significance of Micro-
arrays, SAM, [29]) to quantify changes among feeding
groups. The complete preprocessing workflow is shown
in Figure 1.
Here, a two-step normalization strategy was applied.
Firstly, an independent normalization for each of the five
feeding groups was performed. Secondly, all sets of chips
were normalized regardless of feeding group or time.
Probes that did not exceed an inter-quartile-range
threshold of 0.1 (IQR > 0.1) were filtered. Applying this
cutoff, we excluded 47/94 out of 96 genes/207 probes. A
probe is termed as significantly differentially expressed
when its absolute fold-change exceeds 2 and its mul-
tiple-testing corrected significance threshold (q-value) is
below 0.01.
Visual inspection was done using volcano-plots and
log2(fold-changes) are scattered against their corre-
sponding –log10(p-values) for each probe.
Figure 1 Preprocessing workflow for expression analysis of custom array platform (Alere Technologies). Each rectangle represents one
chip, in which color intensity models measured signal intensities. Higher expression differences correspond to larger rectangles. Each circle
represents physical distortion e.g. an air pocket. Red rectangles are spots that are excluded for further analysis.
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Statistical analysis was performed using SPSS Statistics
Version 19.0 (IBM, Armonk, USA). For the statistical
analysis of fatty acids of milk samples, the linear mixed
model of SPSS was applied. Hence, animals were consid-
ered as subjects and week of lactation as the repeated
effect with an autoregressive covariance structure. Treat-
ment, week of lactation, and the interaction between treat-
ment and week of lactation were considered as factors
for fixed effects. Animals were treated as random effects.
Results are expressed as estimated marginal means
(EMMeans) ± SEM. Statistical analysis of fatty acids of dif-
ferent tissues (liver tissue, retroperitoneal adipose tissue,
muscle tissue, and tissue of the mammary gland) was
performed by comparing the means of the CON groups
with those of the CLA groups using the independent-
samples t-test. Results are expressed as means ± SD. For
all statistical analyses, observed differences are called
significant if the calculated p-value is below 0.05.
Results
Milk samples
Supplementing the diet of dairy cows with equal amounts
of c9,t11-CLA and t10,c12-CLA led to a significant
increase of the two supplemented CLA isomers in milk
lipids. In period 1, amounts of c9,t11-CLA and t10,c12-
CLA increased from 3.5 to 4.4 g/day and from 0.01 to
0.42 g/day (Table 1), respectively. Similar increases were
seen in period 2 (Table 2). Moreover, the proportion of
other CLA isomers, mainly c9,c11-CLA and t9,t11-CLA
also increased significantly in period 1. The rise in the two
supplemented isomers was accompanied by a significant
alteration of the fraction of saturated fatty acids (SFA) in
both periods. SFA decreased from 708 to 585 g/day and
from 781 to 608 g/day in period 1. In period 2, similar
changes in SFA (Table 2) were observed. Due to some sin-
gle de novo-synthesized fatty acids (DSFA) e.g. 6:0, 8:0 and
12:0, the total amount of DSFA was significantly reduced
by treatment in both periods. In contrast, the total amount
of preformed fatty acids (PRFA) did not change. In bothperiods, the sum of fatty acids with 16 carbon atoms was
notably reduced, due to the significant decline of palmitic
acid (16:0), the most abundant fatty acid in milk lipids.
Except for significantly elevated levels of t12-18:1 and c12-
18:1 in period 1, other MUFA were found increased but
failed to reach significance. The fatty acid ratio c9-14:1/
14:0 was significantly reduced in period 1 indicating inhib-
ition of Δ9 desaturase activity.
Mammary gland
At 42 DIM and 105 DIM, the fatty acid profile of the
mammary gland was characterized by elevated concen-
trations of the two supplemented isomers. The t10,c12-
CLA isomer could not be detected in the CON groups
but was present in the CLA groups (Table 3). Although,
a decline in SFA and an increase in monounsaturated
fatty acids (MUFA) were observed at 42 DIM and 105
DIM, the levels were insignificant. At 42 DIM, concen-
trations of both polyunsaturated fatty acids (PUFA) and
total n-6 PUFA were significantly increased mediated
through linoleic acid. At 105 DIM, PUFA and total n-6
PUFA remained unaffected. However, the total percent-
age of t-18:1 acids increased significantly at 42 DIM and
fatty acid ratio remained unaffected (Table 3).
Liver tissue
In liver tissue, t10,c12-CLA was not detected in both
periods 1 and 2 although the proportion of c9,t11-CLA
tended to increase. c12-18:1, as well as linoleic acid (18:2
n-6) were significantly elevated in both periods (Table 4).
In addition, proportions of t-18:1 acids, t10-18:1 and
docosahexenoic acid (DHA; 22:6 n-3) were found in-
creased at 42 DIM but fatty acid ratio was not affected
(Table 4).
M. longissimus
As with retroperitoneal adipose tissue, supplementation
of CLA isomers had no significant effect on the propor-
tion of c9,t11-CLA, and t10,c12-CLA in both periods
(Table 5). The concentration of SFA increased whereas
Table 1 Selected milk lipid fatty acids during period 1 (1 until 42 DIM)
Fatty acid [g/day] Treatment1 SEM P-value
CON CLA Trt Trt x WL2
4:0 37.5 37.0 2.6 0.906 0.528
6:0 27.2 22.9 1.5 0.051 0.496
8:0 15.4 12.1* 0.74 0.005 0.809
10:0 36.9 26.8* 1.6 0.000 0.987
12:0 39.3 27.8* 1.7 0.000 0.926
14:0 11.5 92.4* 4.2 0.005 0.992
c9-14:1 6.3 4.5* 0.36 0.002 0.561
15:0 12.0 10.1* 0.59 0.035 0.991
16:0 301 237* 11.8 0.001 0.199
c9-16:1 12.2 12.3 0.84 0.924 0.436
17:0 6.1 6.0 0.35 0.728 0.658
18:0 97.8 92.1 8.4 0.633 0.402
t6/t7/t8-18:1 1.6 2.1 0.17 0.063 0.663
t9-18:1 2.0 2.3 0.12 0.088 0.414
t10-18:1 4.2 6.8 1.1 0.096 0.822
t11-18:1 7.3 8.7 0.77 0.215 0.240
t12-18:1 2.1 2.6* 0.15 0.030 0.352
t13/t14-18:1 2.3 2.6 0.16 0.227 0.993
c9-18:1 172 183 16.0 0.633 0.336
c11-18:1 8.1 8.5 0.63 0.602 0.649
c12-18:1 1.7 2.1* 0.14 0.032 0.605
c13-18:1 0.91 1.0 0.08 0.662 0.249
18:2 n-6 14 14.8 0.95 0.571 0.016
18:3 n-3 0.23 0.2 0.01 0.104 0.857
CLA
c9,t11-CLA 3.5 4.4* 0.30 0.039 0.787
t10,c12-CLA 0.01 0.42* 0.02 0.000 0.125
Other CLA 0.74 0.97* 0.07 0.022 0.787
Summations
∑ SFA 708 585* 29.5 0.008 0.617
∑ MUFA 230 246 18.9 0.563 0.394
∑ PUFA 25.3 27.8 1.8 0.335 0.143
∑ trans-18:1 24.3 30.7 2.18 0.054 0.998
∑ BCFA3 16.4 15.7 0.74 0.520 0.567
∑ C164 314 249* 12.4 0.002 0.191
∑ de novo5 300 246* 11.7 0.003 0.950
∑ preformed6 350 365 28.2 0.716 0.262
Ratio
c9-14:1/14:0 0.54 0.41* 0.03 0.006 0.434
1Treatment (Trt): cows in the control (CON) group (n = 10) received a control fat supplement, in which the CLA were substituted with stearic acid. Cows in the
conjugated linoleic acid (CLA) group (n = 10) consumed 6 g/d each of trans-10,cis-12 CLA and cis-9,trans-11 CLA.
2Week of lactation; 3BCFA branched-chain fatty acids, 4C16 Sum of 16:0 and c9-16:1.
5de novo: fatty acids <16 carbon atoms; 6preformed: fatty acids >16 carbon atoms.
*Estimated mariginal means (EMMeans) are defined as significant (P < 0.05).
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Table 2 Selected milk lipid fatty acids during period 2 (>42 until 105 DIM)
Fatty acid [g/day] Treatment1 SEM P-value
CON CLA Trt Trt x WL2
4:0 37.3 33.5 1.9 0.186 0.470
6:0 29.8 23.3* 1.6 0.016 0.767
8:0 16.6 11.8* 1.2 0.011 0.824
10:0 41.1 27.5* 3.2 0.015 0.888
12:0 47.1 30.4* 3.8 0.013 0.931
14:0 129 104 8.1 0.059 0.858
c9-14:1 11.0 6x.9 1.3 0.052 0.977
15:0 14.8 10.2 1.5 0.055 0.430
16:0 364 267* 19.7 0.009 0.346
c9-16:1 15.2 12.8 1.3 0.240 0.800
17:0 5.8 5.0 0.4 0.182 0.410
18:0 72.3 72.9 4.5 0.927 0.261
t6/t7/t8-18:1 1.2 1.6 0.15 0.075 0.250
t9-18:1 1.7 2.1 0.14 0.078 0.484
t10-18:1 2.6 4.3 0.62 0.080 0.708
t11-18:1 5.0 6.1 0.38 0.073 0.364
t12-18:1 2.1 2.6 0.20 0.121 0.220
t13/t14-18:1 2.5 2.7 0.21 0.590 0.033
c9-18:1 139 150 8.5 0.375 0.388
c11-18:1 6.0 6.4 0.67 0.671 0.624
c12-18:1 1.9 2.4 0.19 0.075 0.253
c13-18:1 0.7 0.8 0.06 0.664 0.911
18:2 n-6 13.3 14.5 0.97 0.384 0.924
18:3 n-3 0.31 0.24 0.02 0.069 0.253
CLA
c9,t11-CLA 3.4 4.3 0.34 0.093 0.767
t10,c12-CLA 0.00 0.37* 0.04 0.000 0.030
Other CLA 0.73 0.91 0.07 0.078 0.211
Summations
∑ SFA 781 608* 39.9 0.014 0.582
∑ MUFA 199 208 11.5 0.626 0.444
∑ PUFA 24.5 26.8 1.7 0.374 0.762
∑ trans-18:1 19.7 24.7 1.9 0.103 0.254
∑ BCFA3 17.1 16.0 0.81 0.347 0.346
∑ C164 380 280* 20.9 0.010 0.366
∑ de novo5 345 261* 21.4 0.021 0.947
∑ preformed6 282 301 13.9 0.358 0.291
Ratio
c9-14:1/14:0 0.86 0.55 0.10 0.060 1.000
1Treatment (Trt): cows in the control (CON) group (n = 10) received a control fat supplement, in which the CLA were substituted with stearic acid. Cows in the
conjugated linoleic acid (CLA) group (n = 10) consumed 6 g/d each of trans-10,cis-12 CLA and cis-9,trans-11 CLA.
2Week of lactation; 3BCFA branched-chain fatty acids; 4C16 Sum of 16:0 and c9-16:1.
5de novo: fatty acids <16 carbon atoms; 6preformed: fatty acids >16 carbon atoms.
*Estimated mariginal means (EMMeans) are defined as significant (P < 0.05).
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Table 3 Selected fatty acids in lipids of the mammary gland at 42 DIM and 105 DIM of supplementation
Fatty acid [% FAME] Period 1 (42 DIM) Period 2 (105 DIM)
CON CLA CON CLA
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
14:0 9.88 ± 0.70 9.40 ± 2.10 9.10 ± 0.87 9.13 ± 1.67
c9-14:1 0.65 ± 0.19 0.51 ± 0.19 0.83 ± 0.02 0.68 ± 0.27
16:0 32.62 ± 3.16 30.16 ± 4.28 31.41 ± 3.64 29.05 ± 3.13
c9-16:1 1.52 ± 0.16 1.49 ± 0.12 1.84 ± 0.10 1.89 ± 0.25
18:0 10.38 ± 1.43 11.84 ± 2.56 9.80 ± 2.00 11.17 ± 2.05
t6/t7/t8-18:1 0.08 ± 0.05 0.14 ± 0.02* 0.13 ± 0.02 0.17 ± 0.07
t9-18:1 0.20 ± 0.01 0.25 ± 0.02* 0.23 ± 0.01 0.28 ± 0.06
t10-18:1 0.22 ± 0.06 0.37 ± 0.09* 0.29 ± 0.05 0.68 ± 0.68
t11-18:1 0.65 ± 0.13 0.77 ± 0.04 0.68 ± 0.06 0.89 ± 0.37
t12-18:1 0.21 ± 0.03 0.29 ± 0.02* 0.27 ± 0.02 0.31 ± 0.05
t13/t14-18:1 ND ND ND ND
c9-18:1 20.45 ± 2.88 22.46 ± 3.11 22.34 ± 2.56 22.82 ± 5.00
c11-18:1 0.88 ± 0.13 1.06 ± 0.11* 0.84 ± 0.17 1.12 ± 0.24
c12-18:1 0.22 ± 0.03 0.31 ± 0.01* 0.28 ± 0.02 0.33 ± 0.04*
c13-18:1 0.08 ± 0.02 0.10 ± 0.01 0.10 ± 0.02 0.11 ± 0.02
18:2 n-6 2.52 ± 0.40 3.43 ± 0.57* 3.08 ± 0.27 4.02 ± 1.23
18:3 n-3 0.42 ± 0.09 0.53 ± 0.09 0.41 ± 0.03 0.49 ± 0.10
20:4 n-6 0.37 ± 0.08 0.46 ± 0.11 0.48 ± 0.06 0.65 ± 0.14
20:5 n-3 0.13 ± 0.03 0.17 ± 0.05 0.12 ± 0.01 0.16 ± 0.03*
22:5 n-3 0.25 ± 0.05 0.32 ± 0.10 0.27 ± 0.03 0.33 ± 0.07
22:6 n-3 0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01
CLA
c9,t11-CLA 0.37 ± 0.03 0.49 ± 0.11 0.51 ± 0.06 0.73 ± 0.34
t10,c12-CLA ND 0.05 ± 0.01 ND 0.05 ± 0.01
Other CLA 0.06 ± 0.02 0.09 ± 0.01* 0.07 ± 0.02 0.10 ± 0.04
Summations
∑ SFA 69.04 ± 3.20 64.84 ± 3.74 65.13 ± 2.65 62.13 ± 5.51
∑ MUFA 26.33 ± 2.89 29.02 ± 2.90 29.12 ± 2.76 30.59 ± 4.73
∑ PUFA n-3 0.91 ± 0.14 1.17 ± 0.25 0.93 ± 0.05 1.12 ± 0.18
∑ PUFA n-6 3.29 ± 0.55 4.34 ± 0.71* 4.23 ± 0.33 5.27 ± 1.41
∑ PUFA incl. CLA 4.64 ± 0.69 6.14 ± 0.86* 5.74 ± 0.39 7.28 ± 1.94
∑ trans-18:1 1.81 ± 0.34 2.37 ± 0.20* 2.11 ± 0.15 2.87 ± 1.25
Ratio
c9-14:1/14:0 0.07 ± 0.02 0.05 ± 0.01 0.09 ± 0.01 0.07 ± 0.02
Cows in the control (CON) group (n = 5) of each period received a control fat supplement, in which the CLA were substituted with stearic acid. Cows in the
conjugated linoleic acid (CLA) group (n = 5) of each period consumed 6 g/d each of trans-10,cis-12 CLA and cis-9,trans-11 CLA.
*Means ± SD for each period are defined significant (P < 0.05).
ND not detected.
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http://www.lipidworld.com/content/12/1/96the levels of MUFA considerably decreased in period 2
which is due to a significant decline of the most abun-
dant oleic acid (c9-18:1) in muscle tissue. With the ex-
ception of c9-14:1/14:0, ratios of other fatty acids were
not significantly affected by CLA supplementation.Retroperitoneal tissue
At 42 DIM and 105 DIM, the fatty acid profile of retro-
peritoneal adipose tissue showed no significant changes
with regard to the proportion of c9,t11-CLA. However,
the proportion of the t10,c12-CLA isomer changed from
Table 4 Selected fatty acids in liver lipids at 42 DIM and 105 DIM of supplementation
Fatty acid [% FAME] Period 1 (42 DIM) Period 2 (105 DIM)
CON CLA CON CLA
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
14:0 1.18 ± 0.69 1.46 ± 0.43 0.69 ± 0.24 0.67 ± 0.17
c9-14:1 0.19 ± 0.13 0.18 ± 0.14 0.16 ± 0.11 0.07 ± 0.08
16:0 14.37 ± 4.59 13.95 ± 1.92 10.93 ± 1.54 11.42 ± 3.75
c9-16:1 1.35 ± 0.77 1.36 ± 0.46 0.76 ± 0.31 0.65 ± 0.31
18:0 28.41 ± 4.93 28.44 ± 2.35 32.34 ± 1.16 31.47 ± 4.48
t6/t7/t8-18:1 0.03 ± 0.02 0.05 ± 0.01 0.04 ± 0.01 0.05 ± 0.03
t9-18:1 0.13 ± 0.02 0.16 ± 0.02 0.15 ± 0.03 0.16 ± 0.07
t10-18:1 0.08 ± 0.02 0.15 ± 0.02* 0.08 ± 0.03 0.30 ± 0.42
t11-18:1 0.56 ± 0.11 0.74 ± 0.13 0.49 ± 0.08 0.80 ± 0.52
t12-18:1 0.22 ± 0.08 0.31 ± 0.04 0.24 ± 0.04 0.27 ± 0.03
t13/t14-18:1 0.60 ± 0.44 0.50 ± 0.14 0.79 ± 0.05 0.62 ± 0.38
c9-18:1 15.31 ± 4.49 14.21 ± 2.28 11.96 ± 0.81 12.10 ± 5.46
c11-18:1 1.79 ± 0.10 1.92 ± 0.12 1.56 ± 0.15 1.60 ± 0.30
c12-18:1 0.18 ± 0.02 0.29 ± 0.05* 0.18 ± 0.04 0.27 ± 0.07*
c13-18:1 0.15 ± 0.01 0.17 ± 0.05 0.19 ± 0.04 0.16 ± 0.06
18:2 n-6 9.04 ± 0.67 9.93 ± 0.25* 9.06 ± 1.17 11.13 ± 1.12*
18:3 n-3 0.83 ± 0.30 0.99 ± 0.27 0.58 ± 0.09 0.79 ± 0.23
20:4 n-6 5.43 ± 0.75 5.37 ± 1.05 6.10 ± 0.72 6.02 ± 0.58
20:5 n-3 1.50 ± 0.47 1.55 ± 0.21 1.24 ± 0.13 1.29 ± 0.43
22:5 n-3 3.70 ± 0.81 3.76 ± 0.58 4.12 ± 0.44 4.12 ± 0.97
22:6 n-3 0.62 ± 0.09 0.79 ± 0.11* 0.43 ± 0.07 0.53 ± 0.14
CLA
c9,t11-CLA 0.24 ± 0.10 0.29 ± 0.07 0.19 ± 0.06 0.26 ± 0.13
t10,c12-CLA ND ND ND ND
Other CLA 0.14 ± 0.10 0.12 ± 0.05 0.16 ± 0.02 0.10 ± 0.06
Summations
∑ SFA 48.95 ±1.11 49.08 ± 0.57 49.08 ± 0.97 48.62 ± 1.75
∑ MUFA 22.03 ± 5.11 21.58 ± 3.03 17.99 ± 1.21 18.57 ± 5.26
∑ PUFA n-3 7.71 ± 1.41 8.34 ± 0.48 7.68 ± 0.66 7.84 ± 1.58
∑ PUFA n-6 20.92 ± 3.74 20.59 ± 2.30 24.90 ± 1.26 24.60 ± 2.77
∑ PUFA incl. CLA 29.02 ± 4.96 29.34 ± 2.50 32.93 ± 1.79 32.81 ± 3.89
∑ trans-18:1 2.10 ± 0.43 2.51 ± 0.17 2.42 ± 0.17 2.95 ± 1.33
Ratio
c9-14:1/14:0 0.18 ± 0.12 0.11 ± 0.06 0.21 ± 0.11 0.11 ± 0.10
Cows in the control (CON) group (n = 5) of each period received a control fat supplement, in which the CLA were substituted with stearic acid. Cows in the
conjugated linoleic acid (CLA) group (n = 5) of each period consumed 6 g/d each of trans-10,cis-12 CLA and cis-9,trans-11 CLA.
*Means ± SD for each period are defined significant (P < 0.05).
ND not detected.
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http://www.lipidworld.com/content/12/1/96non-detectable to 0.02% of FAME only at 105 DIM. Fur-
thermore, a significant elevation of n-3 PUFA from 0.20
to 0.25% of FAME was observed at 105 DIM. Other fatty
acid parameters remained unaffected (see Additional file 2).Expression data
The above mentioned effects observed with FAME were
analyzed on gene expression level in mammary gland
where the highest changes in fatty acid composition
Table 5 Selected fatty acids in lipids of M. longissimus at 42 DIM and 105 DIM of supplementation
Fatty acid [% FAME] Period 1 (42 DIM) Period 2 (105 DIM)
CON CLA CON CLA
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
14:0 1.73 ± 0.37 1.79 ± 0.28 1.74 ± 0.31 1.67 ± 0.52
c9-14:1 0.49 ± 0.20 0.41 ± 0.05 0.57 ± 0.20 0.36 ± 0.25
16:0 25.42 ± 2.39 25.38 ± 1.52 25.55 ± 1.38 25.09 ± 2.32
c9-16:1 3.74 ± 1.01 3.75 ± 0.48 4.11 ± 0.80 3.61 ± 1.15
18:0 13.54 ± 1.31 13.38 ± 0.82 12.07 ± 1.26 13.59 ± 1.68
t6/t7/t8-18:1 0.12 ± 0.02 0.12 ± 0.02 0.14 ± 0.01 0.13 ± 0.02
t9-18:1 0.30 ± 0.02 0.31 ± 0.04 0.32 ± 0.02 0.32 ± 0.03
t10-18:1 0.24 ± 0.02 0.26 ± 0.01 0.29 ± 0.04 0.36 ± 0.07
t11-18:1 0.52 ± 0.05 0.54 ± 0.09 0.52 ± 0.05 0.53 ± 0.10
t12-18:1 0.13 ± 0.02 0.13 ± 0.01 0.14 ± 0.01 0.15 ± 0.02
t13/t14-18:1 ND ND ND ND
c9-18:1 43.01 ± 1.76 40.94 ± 3.22 43.41 ± 1.38 41.04 ± 1.76*
c11-18:1 1.81 ± 0.22 1.90 ± 0.19 2.09 ± 0.34 1.78 ± 0.17
c12-18:1 0.12 ± 0.05 0.12 ± 0.04 0.13 ± 0.03 0.14 ± 0.05
c13-18:1 0.27 ± 0.05 0.20 ± 0.02 0.30 ± 0.08 0.18 ± 0.08*
18:2 n-6 2.29 ± 0.52 3.18 ± 1.36 2.53 ± 1.04 3.22 ± 1.14
18:3 n-3 0.36 ± 0.09 0.52 ± 0.17 0.34 ± 0.08 0.43 ± 0.12
20:4 n-6 0.66 ± 0.18 1.04 ± 0.69 0.69 ± 0.38 1.15 ± 0.74
20:5 n-3 0.14 ± 0.05 0.29 ± 0.23 0.14 ± 0.10 0.26 ± 0.18
22:5 n-3 0.25 ± 0.06 0.42 ± 0.23 0.24 ± 0.16 0.43 ± 0.24
22:6 n-3 ND 0.03 ± 0.03 ND 0.02 ± 0.02
CLA
c9,t11-CLA 0.19 ± 0.03 0.19 ± 0.04 0.19 ± 0.03 0.21 ± 0.03
t10,c12-CLA ND ND ND ND
Other CLA 0.07 ± 0.01 0.07 ± 0.02 0.08 ± 0.01 0.08 ± 0.02
Summations
∑ SFA 44.32 ± 1.21 44.58 ± 1.57 42.86 ± 0.98 44.48 ± 0.75*
∑ MUFA 51.30 ± 1.09 49.11 ± 2.99 52.42 ± 2.18 49.08 ± 2.11*
∑ PUFA n-3 0.82 ± 0.18 1.35 ± 0.69 0.79 ± 0.36 1.22 ± 0.60
∑ PUFA n-6 3.30 ± 0.71 4.69 ± 2.27 3.65 ± 1.51 4.91 ± 2.15
∑ PUFA incl. CLA 4.38 ± 0.91 6.31 ± 2.95 4.71 ± 1.82 6.44 ± 2.76
∑ trans-18:1 1.46 ± 0.13 1.46 ± 0.12 1.49 ± 0.04 1.60 ± 0.22
Ratio
c9-14:1/14:0 0.27 ± 0.06 0.23 ± 0.03 0.32 ± 0.07 0.20 ± 0.07*
Cows in the control (CON) group (n = 5) of each period received a control fat supplement, in which the CLA were substituted with stearic acid. Cows in the
conjugated linoleic acid (CLA) group (n = 5) of each period consumed 6 g/d each of trans-10,cis-12 CLA and cis-9,trans-11 CLA.
*Means ± SD for each period are defined significant (P < 0.05).
ND not detected.
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http://www.lipidworld.com/content/12/1/96apart from milk have been observed. Results of the
probe-level SAM analysis between the 2 feeding groups
in periods 1 and 2 are shown in Figure 2.
None of the compared periods yielded results sufficient
to draw final conclusions with respect to alterations at
expression levels caused by feeding the CLA mixture. Inaddition to the described periods, further group combi-
nations over feeding and time were also inspected. The
strongest (insignificant) changes were observed for dif-
ferent time-points and feeding groups (e.g. CON0 -
CLA105). Based on this data, CLA supplementation could
thus affect speed rather than the amount of metabolites
Figure 2 Results of expression analysis on probe level for the 2 feeding groups (CON and CLA) in period 1 (left) and period 2 (right)
are shown as volcano-plots. A probe is called significant if its absolute fold-change is above 2 (|log2(fold-change)| > 1) and the corresponding
p-value is below 0.01 (–log10(p-Value) > 2).
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http://www.lipidworld.com/content/12/1/96participating in the underlying processes. Another explan-
ation for the insignificant results could be due to other
confounding factors which affect and obscure the changes.
A possible confounding factor could be the health status of
the animal at day of measurement.
Discussion
In the present study, both measurement periods were char-
acterized by elevated concentrations of the supplemented
isomers in milk lipids following supplementation with
5.7 g/d c9,t11-CLA and 6 g/d t10,c12-CLA (Tables 1 and 2).
According to Baumgard et al. [7], elevated concentrations
of t10,c12-CLA are linked to reductions in milk fat content
and/or milk fat yield in a dose-dependent manner.We have
previously shown that the given dose of CLA was potent
towards reducing the content of milk fat significantly by
14.1% in period 1 and by 25.4% in period 2. Further, CLA
led to a decrease in the milk fat yield by 17.1% in period 2 in
early lactation [20]. This is in accordance with data from the
study by Moallem et al. [30], in which 4.7 g/d t10,c12-CLA
and 4.7 g/d c9,t11-CLA of the same lipid-encapsulated
supplement was used and showed similar reductions in
milk fat content (13%) and milk fat yield (9%, insignificant)
compared to period 1 of the present study. Further, our
results are also supported by observations from Giesy et al.
[31], who reported a reduction in milk fat content of
approximately 14% by supplementing four CLA isomers as
a mixture that, amongst other CLA isomers, contained
4.4 g/d or 8.6 g/d of t10,c12-CLA. Although the main effect
on the milk fat-lowering effect is ascribed to t10,c12-CLA, a
possible participation or interaction of the other isomers
(e.g. c9,t11-CLA, c8,t10-CLA or c11,t13-CLA) cannot be
excluded.
The reduction in milk fat content and milk fat yield in
the present study is marked by a significant decrease insingle DSFA (8:0, 10:0 and 12:0) as well as 16:0. The latter
fatty acid originated to about 50% each from de novo-syn-
thesis and from circulating fatty acids. Castaneda-Gutierrez
et al. [32] showed similar results on single DSFA, ΣC16, and
fatty acid ratios with the exception that the latter were
unaffected when provided with 9.2 g/d t10,c12-CLA as part
of a rumen-protected CLA-mix supplement as Ca-salts.
Interestingly, Bernal-Santos et al. [33] used a CLA-mix
consisting of four CLA isomers (c9,t11-CLA; t10,c12-CLA;
t8,c10-CLA and c11,t13-CLA) that provided 8.8 g/d t10,
c12-CLA as Ca-salts, and reported no significant effect on
DSFA, except for ΣC16 fatty acids. In the study [33], the
fatty acid ratios also remained unaffected. As proposed by
Baumgard et al. [34] and Peterson et al. [8], low doses of t10,
c12-CLA show no effect on Δ9-desaturase activity despite
significant reduction of milk fat content and/or milk fat
yield. In contrast, abomasal infusions of several doses of t10,
c12-CLA resulted in alterations of fatty acid ratios indicat-
ing inhibition of Δ9-desaturase activity [7,14,34,35]. The
c9-14:1/14:0 ratio provides a suitable estimation of Δ9
desaturase activity that is specific for the mammary gland
and thus for milk lipids, given that 14:0 and c9-14:1 are
almost exclusively derived by de novo-synthesis in the
mammary gland [36]. In the present study, we could show a
significant reduction of the c9-14:1/14:0 ratio in period 1,
indicating inhibition of Δ9 desaturase activity. This is in ac-
cordance with our observations on DSFA and ΣC16 in the
present study. In addition, because the amount of c12-18:1
was significantly elevated in period 1, it might have further
enhanced the inhibition ofΔ9 desaturase activity [37].
MFD, either diet induced or mediated by t10,c12-CLA,
is caused by down-regulation of several transcription
factors [13,38] and enzymes involved in de novo-synthe-
sis, desaturation, and elongation [14,39] processes. Based
on our gene expression analysis, we did not observe a
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enzymes or transcription factors in lipid metabolism in
the mammary gland that could explain the reduction of
the c9-14:1/14:0 ratio.
T-18:1 acids, intermediates of partial hydrogenation of
unsaturated fatty acids, especially of linoleic acid are often
linked to diets that causeMFD [40]. Several research groups
using rumen-protected CLA, observed a significant in-
crease of single 18:1 fatty acids (e.g., t9-, t10-, t11-18:1) in
milk fat [32,33,41]. The results of our study concur with
these findings as we observed similar elevations in single
t-18:1 acids which were close to significance in both periods
(Tables 1 and 2).
Increased concentrations of t-18:1 acids, especially
t10-18:1 and t11-18:1, suggest a poor protection rate of
the supplemented CLA. Investigating the duodenal avail-
ability of the same lipid-encapsulated CLA supplement,
Pappritz et al. [42] showed protection rates of 16% and
5% after providing 3 and 8 g/d of t10,c12-CLA, respect-
ively, and assumed an impaired rumen protection due to
the pelleting process. Because we used the same condi-
tions for preparing of the CLA supplement, it is most
likely that unprotected CLA serve as potential substrates
for microbial alterations and, consequently, lead to ele-
vated concentrations of t-18:1 acids. Since Shingfield
et al. [10] recently showed that a mixture of t-18:1 acids,
in particular t10-18:1 and t11-18:1, are capable of indu-
cing MFD, it is most likely that the reduction of milk fat
yield and milk fat content in the present study is caused
by both t10,c12-CLA and, to a lesser extent by t10-18:1.
CLA, originally identified in fried ground beef, gained
considerable attention because of its anticarcinogenic ef-
fects [43]. Other studies with CLA supplemented in feed
either as a mixture or as pure isomers showed specific
changes in body composition that are almost exclusively
due to the t10,c12-CLA isomer [44,45]. Jahreis et al. [46]
reported in their summary that liver and adipose tissue,
and to a certain extent muscle tissue are most affected by
CLA. However, these changes are not consistent among
species. The majority of studies investigating the effects of
CLA on body composition and/or fatty acid distribution
have mainly been conducted in rodents and pigs. The few
studies in dairy cattle, concentrated on the mammary
gland as the principal object of research.
In the present study, supplementation with CLA showed
only marginal effects on the fatty acid distribution of the
above mentioned tissues. Despite supplementing a mix-
ture with equal amounts of both isomers, t10,c12-CLA
was detected only in the mammary gland (Table 3) and
retroperitoneal adipose tissue (Additional file 2), and not
in the lipids of liver and M. longissimus. Kramer et al. [47]
showed that the distribution of the different CLA isomers
incorporated into liver and heart lipids in pigs is by no
means equal for all lipid classes but rather specific for eachindividual CLA isomer. Furthermore, Kramer et al. [47]
showed that the percentage of t10,c12-CLA is generally
low in liver lipids compared to c9,t11-CLA. This observa-
tion has been previously reported [19,48] and is explained
as a preferable conversion of t10,c12-CLA through elong-
ation and desaturation or elevated beta-oxidation in liver
and muscle which finally results in lower concentrations
than the supplementation might predict [44,49]. Further,
we have to concede that emerging isomerization products
due to transesterification with BF3 may have reduced the
already low concentration of t10,c12-CLA.
Mice fed diets with different amounts of CLA, in par-
ticular pure t10,c12-CLA or in combination with c9,t11-
CLA, exhibited decreased concentrations of linoleic acid
and increased accumulation of oleic acid in liver lipids
which, in turn, led to significantly higher liver weights
[16,19,50,51]. This is in contrast to the results of the
present study, where liver weights increased in a fashion
typical during early lactation but independent of CLA
supplementation [20]. Furthermore, changes of the fatty
acid distribution in liver lipids were limited to linoleic
acid and c12-18:1 in both periods, and to t10-18:1 and
DHA in period 1 (Table 4). Increased percentages of
linoleic acid and DHA in liver lipids in the present study
could be explained by a shift in the triglyceride:phospho-
lipid ratio because phospholipids contain higher portions
of long-chain fatty acids [52]. Based on an average dry
matter intake of 15.3 kg in both periods, the dose of the
two supplemented CLA isomers at 0.04% is low in the
present study compared to approximately 0.5% – 1%
used in rodent or pig models [53]. C9,t11- and t10,c12-
CLA, administered as pure isomers are described to
have opposite effects on body composition and fatty acid
distribution in mice. For example, Kelley et al. [51]
showed a decrease of oleic acid in total lipids of liver,
retroperitoneal adipose tissue, and spleen after adminis-
tration of 0.5% c9,t11-CLA, whereas 0.5% t10,c12-CLA
increased oleic acid in liver and heart lipids, and de-
creased linoleic and arachidonic acid in liver lipids.
Studies in rodents showed that the retroperitoneal adi-
pose tissue was most sensitive to CLA [54-56]. Although
we observed a significant reduction of the retroperiton-
eal adipose tissue as part of the empty body weight in
dairy cattle [20], this effect is not necessarily linked to a
changed fatty acid distribution as the present study
demonstrated.
Conclusion
In the present study, we showed that the daily
supplemented dose of 5.7 g/d c9,t11-CLA and 6.0 g/d t10,
c12-CLA predominantly affected the mammary gland and,
thus milk lipids by decreasing DSFA and C16, leading to
MFD. The significantly reduced c9-14:1/14:0 ratio and
considerably increased c12-18:1 isomer underline these
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http://www.lipidworld.com/content/12/1/96observations. However, except for elevated concentrations
of certain single fatty acids in liver and muscle tissue, the
effects on fatty acid distribution in different body tissues
remained marginal at this dose of CLA and could be the
result of a slight shift in the triglyceride:phospholipid
ratio.
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